Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.16, Zacks reports.
Atea Pharmaceuticals Stock Performance
Shares of AVIR stock traded up $0.15 on Friday, hitting $2.74. The company had a trading volume of 528,557 shares, compared to its average volume of 306,861. The firm has a market cap of $234.49 million, a P/E ratio of -1.32 and a beta of 0.17. The stock's 50-day moving average is $2.91 and its two-hundred day moving average is $3.09. Atea Pharmaceuticals has a twelve month low of $2.46 and a twelve month high of $4.15.
Analyst Ratings Changes
A number of brokerages have recently commented on AVIR. Morgan Stanley cut their price target on Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating on the stock in a research note on Friday, April 11th. William Blair reissued an "outperform" rating on shares of Atea Pharmaceuticals in a research note on Friday, March 7th.
View Our Latest Report on AVIR
Atea Pharmaceuticals Company Profile
(
Get Free Report)
Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.
Featured Articles
Before you consider Atea Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.
While Atea Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
